Detalhe da pesquisa
1.
Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
J Infect Dis
; 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38848312
2.
Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial.
Clin Infect Dis
; 75(1): e585-e593, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35234868
3.
Bridging the gap: identifying factors impacting mRNA severe acute respiratory syndrome coronavirus 2 vaccine booster response in people with HIV-1.
AIDS
; 38(2): 217-222, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830908
4.
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2).
Open Forum Infect Dis
; 10(4): ofad150, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37035486
5.
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2).
Open Forum Infect Dis
; 10(11): ofad536, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38023564
6.
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV.
AIDS
; 36(10): 1465-1468, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876706
7.
A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
Trials
; 22(1): 724, 2021 Oct 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34674742